These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1804 related articles for article (PubMed ID: 8586465)
1. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function. Kley N; Whaley J; Seizinger BR Glia; 1995 Nov; 15(3):297-307. PubMed ID: 8586465 [TBL] [Abstract][Full Text] [Related]
2. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome? Kley N; Seizinger BR Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520 [TBL] [Abstract][Full Text] [Related]
3. [Neurofibromatosis type 2 (NF2)]. Araki N; Takeshima H; Saya H Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136 [TBL] [Abstract][Full Text] [Related]
4. NF2: the wizardry of merlin. Xiao GH; Chernoff J; Testa JR Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860 [TBL] [Abstract][Full Text] [Related]
5. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Kanno H; Kondo K; Ito S; Yamamoto I; Fujii S; Torigoe S; Sakai N; Hosaka M; Shuin T; Yao M Cancer Res; 1994 Sep; 54(18):4845-7. PubMed ID: 8069849 [TBL] [Abstract][Full Text] [Related]
6. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Chen F; Kishida T; Yao M; Hustad T; Glavac D; Dean M; Gnarra JR; Orcutt ML; Duh FM; Glenn G Hum Mutat; 1995; 5(1):66-75. PubMed ID: 7728151 [TBL] [Abstract][Full Text] [Related]
7. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Gnarra JR; Lerman MI; Zbar B; Linehan WM Semin Oncol; 1995 Feb; 22(1):3-8. PubMed ID: 7855617 [TBL] [Abstract][Full Text] [Related]
8. [Does hemangioblastoma exist outside von Hippel-Lindau disease?]. Richard S; Beigelman C; Gerber S; Van Effenterre R; Gaudric A; Sahel M; Binaghi M; De Kersaint-Gilly A; Houtteville JP; Brunon JP Neurochirurgie; 1994; 40(3):145-54. PubMed ID: 7723921 [TBL] [Abstract][Full Text] [Related]
9. [Von Hippel-Lindau disease and central nervous system hemangioblastoma. Progress in genetics and clinical management]. Richard S; Martin S; David P; Decq P Neurochirurgie; 1998 Nov; 44(4):258-66. PubMed ID: 9864697 [TBL] [Abstract][Full Text] [Related]
10. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens. Zhuang Z; Gnarra JR; Dudley CF; Zbar B; Linehan WM; Lubensky IA Mod Pathol; 1996 Aug; 9(8):838-42. PubMed ID: 8871925 [TBL] [Abstract][Full Text] [Related]
11. von Hippel-Lindau disease: recent advances and therapeutic perspectives. Richard S; Expert Rev Anticancer Ther; 2003 Apr; 3(2):215-33. PubMed ID: 12722881 [TBL] [Abstract][Full Text] [Related]
12. Multifocal bilateral renal cell carcinoma and retinal angiomas in a patient with de novo von Hippel-Lindau disease: identification of a new germline mutation. Sessa A; Battini G; Meroni M; Pitingolo F; Righetti M; Ciotti P; Di Maria E; Bellone E; Ajmar F; Mandich P J Nephrol; 2005; 18(2):209-12. PubMed ID: 15931650 [TBL] [Abstract][Full Text] [Related]
13. [Molecular biological analysis of neurofibromatosis type 2 gene]. Ichimura K; Yuasa Y Nihon Rinsho; 1993 Sep; 51(9):2462-6. PubMed ID: 8411729 [TBL] [Abstract][Full Text] [Related]
14. [From gene to disease; Von Hippel-Lindau disease]. Hes FJ; Los M; van der Luijt RB Ned Tijdschr Geneeskd; 2002 Jul; 146(29):1364-7. PubMed ID: 12162174 [TBL] [Abstract][Full Text] [Related]
15. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001 [TBL] [Abstract][Full Text] [Related]
17. Constitutional von Hippel-Lindau (VHL) gene deletions detected in VHL families by fluorescence in situ hybridization. Pack SD; Zbar B; Pak E; Ault DO; Humphrey JS; Pham T; Hurley K; Weil RJ; Park WS; Kuzmin I; Stolle C; Glenn G; Liotta LA; Lerman MI; Klausner RD; Linehan WM; Zhuang Z Cancer Res; 1999 Nov; 59(21):5560-4. PubMed ID: 10554035 [TBL] [Abstract][Full Text] [Related]
18. Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease. Phillips JL; Ghadimi BM; Wangsa D; Padilla-Nash H; Worrell R; Hewitt S; Walther M; Linehan WM; Klausner RD; Ried T Genes Chromosomes Cancer; 2001 May; 31(1):1-9. PubMed ID: 11284029 [TBL] [Abstract][Full Text] [Related]
19. Juvenile renal cell carcinoma as first manifestation of von Hippel-Lindau disease. Granata A; Sessa A; Righetti M; Cordaro S; Leone G; Figura M; Fatuzzo P; Rapisarda F; Di Maria E; Ciotti P; Mandich P; Nardo A; Ferrone M; Gallone S; Liuzzo G J Nephrol; 2004; 17(2):306-10. PubMed ID: 15293534 [TBL] [Abstract][Full Text] [Related]
20. Mutations of the VHL tumour suppressor gene in renal carcinoma. Gnarra JR; Tory K; Weng Y; Schmidt L; Wei MH; Li H; Latif F; Liu S; Chen F; Duh FM Nat Genet; 1994 May; 7(1):85-90. PubMed ID: 7915601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]